LOW DOSE IL-2 FOR THE TREATMENT OF CROHN'S DISEASE
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and maximum effective dose (MED) of
Interleukin-2 in subjects with moderate-to-severe crohn's disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital